poisar

Stocks · News reference

Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $89

Jul 21, 2026, 1:46 PMBenzinga Newsdesk

Guggenheim analyst Brad Canino maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $106 to $89.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IONS
Source
benzinga
Observed
Jul 21, 2026, 1:46 PM
Checked
Jul 21, 2026, 1:46 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 26, 2026, 5:00 PMDelveinsight

    Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

    The multiple system atrophy (MSA) clinical trial pipeline is experiencing significant momentum with 22+ companies developing 24+ pipeline drugs. The pipeline is diversifying beyond traditional approaches to include oral small molecules, cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors. Recent developments include Alterity Therapeutics achieving FDA alignment on Phase III for ATH434, Teva receiving Fast Track designation for TEV-56286, and iRegene Therapeutics enrolling the first patient in a randomized controlled trial for NouvNeu004 in China.

    Read original at globenewswire-inc
    HLBAYTEVAATHEIONS